San Jose, CA (Vocus/PRWEB) February 22, 2011
G-protein coupled receptors (GPCR) represents one of the most potent class of drug targets, and presently constitutes an important part of modern medicinal chemistry. Drugs targeting GPCRs have superior therapeutic benefits, as they are more active at cell surface. The importance of GPCRs can be put into perspective by the fact that approximately 45% to 50% of all pharmaceutical drugs in the marketplace target G-protein coupled receptors, making it one of the most vital classes of proteins in the genome. Given the fact that GPCRs are the most druggable class of drug targets, with estimates pointing towards more than 100,200 GPCRs in the human genome being druggable, identifying modulators of G protein-coupled receptors (GPCRs) is of critical interest to the pharmaceutical industry. A druggable GPCR is defined as a GPCR structure that contributes towards a disease phenotype, and which can be can be reversed, influenced or modified by small molecule drugs. And market opportunities in the future hinges onto the ability to convert these clinically significant and relevant membrane structures/genes into high performance, potent drugs.
A sanguine future lies in wait for GPCRs in the pharmaceutical world, with recent studies overthrowing the conventional wisdom that GPCRs mediate signals only through G proteins. With research supported evidence that GPCRs are capable of sending extraneous signals into the cell through alternate pathways, such as, Jak2 kinase, and protein kinase C, opens up a new window of research possibilities and drug commercialization opportunities. Research in GPCR is poised to turn competitive with research overcrowding in traditional GPCR binding sites expected to result in shifting preference among researchers to focus on non-traditional GPCR binding sites i.e. allosteric (nonorthosteric sites). While a large percentage of pharma companies’ focus on antagonists as GPCR targets and on protein-dependent pathways, companies focusing on alternate G-protein-independent pathways are seen as more likely to succeed, given the higher therapeutic outcomes in this space.
Another promising area of drug discovery in the G-Protein Coupled Receptors (GPCRs) space is “deorphanizing” the currently orphan GPCRs. With over 150 GPCRs for which endogenous ligand has not been identified till date, orphan GPCRs are a potential laden area for therapeutic targets, and is poised to become the new name of the game, as scientists embark on this largely uncharted path of revelation and discovery.
Players in the marketplace include 7TM Pharma A/S, Actelion Pharmaceuticals Ltd., Acure Pharma AB, Arena Pharmaceuticals Inc., Addex Pharmaceuticals, Cara Therapeutics Inc., DiscoveRx Corporation, Dimerix Bioscience Pty Ltd, Euroscreen SA, Millipore Corporation, and Trevena Inc, among others.
The research report titled “G-Protein Coupled Receptors (GPCRs): A Global Market Report” announced by Global Industry Analysts, Inc., provides a review of noteworthy market trends, issues, technology overview and key strategic industry activities. This single segment study provides market estimates and projections in (in US$ Billion) for the global market.
For more details about this market research report, please visit – http://www.strategyr.com/G_Protein_Coupled_Receptors_GPCRs_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world’s largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/
# # #